Compare Davita Inc (DVA) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Synchrony Financial — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Synchrony Financial trades at $78.37 (market cap $25.44B). The key difference: Synchrony Financial is far larger — about 2.2× Davita Inc's market cap, and Synchrony Financial pays a 1.74% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | SYF | |
|---|---|---|
Market Cap | $11.72B | $25.44B |
Sector | Health | Financials |
52-Week High | $240.96 | $88.47 |
52-Week Low | $103.87 | $63.78 |
Enterprise Value | $24.44B | — |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Synchrony Financial (SYF) trades at $78.59, down 0.1% on the day, with a bullish technical outlook supported by moving averages and strong institutional backing. The stock shows robust fundamentals with a P/E of 8.02, net income margin of 23.4%, and consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.59 versus $2.14 expected. Recent news highlights partnerships like CareCredit's integration with Stripe, enhancing growth prospects.
SYF presents a compelling buy opportunity with a consensus price target of $86.33, offering ~10% upside, driven by aggressive buybacks, stable credit trends, and positive analyst sentiment (62.5% buy ratings). Risks include potential consumer spending slowdowns and competitive pressures in the financial services sector, but strong cash flow and dividend payments support shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
